OTHR-02. An international accelerator programme for novel brain tumour therapies: Early impact and lessons learned
Why this work is in the frame
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Bibliographic record
Abstract
Abstract Developing a comprehensive translational programme for brain tumours involves navigating numerous challenges, including robustness of preclinical studies, safety, clinical trial design, understanding and addressing regulatory requirements, and funding. Recognising the difficulty of this journey, the Brain Tumour Research Novel Therapeutics Accelerator (BTR-NTA) was launched in 2023. The BTR-NTA is an accelerator programme providing independent expert guidance to de-risk drug or device development through systematic evaluation. The international, multidisciplinary BTR-NTA Committee spans expertise across the entire therapeutic development pipeline. Supported by Brain Tumour Research, the BTR-NTA programme is free for academic applicants. Researchers at any stage of therapeutic development may apply to BTR-NTA. Accepted applicants receive up to 240 hours of expert input, with feedback on strengths, identification of potential risks, and guidance on next steps. As part of the BTR-NTA review, the applicants and Committee meet in-person to constructively evaluate and discuss the proposed therapeutic strategy. Since the launch of BTR-NTA in 2023, 23 international groups have applied to the programme, eleven therapeutics have been advanced to the in-person review by the BTR-NTA Committee, and 34 multidisciplinary experts have been involved. All applicants who provided feedback on the programme intended to refine their future work based on the Committee’s input, 83% said the process provided new insights or ideas they had not previously considered, and the average rating of the programme’s usefulness was 9.7 out of 10. A number of common challenges to developing therapies in the brain tumour field have been identified and these lessons can be shared with the wider brain tumour community to help accelerate the translation of future therapies. The ultimate goal of the BTR-NTA programme is to help researchers with a potential therapy for brain tumours navigate the development journey and reach the clinic in an efficient way.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it